Please assess the completion status of the following clinical trial:

Trial Title: Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with confirmed infection by SARS-CoV-2~* Hyperglycemia higher than 140 mg/dl~* Patients accepting oral medications~* Both sex~* Older than 18 years of age~* Patients who accept to participate in the study and sign the consent form~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy~* Hyperosmolar hyperglycemic state or diabetic ketoacidosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DPP4 inhibitor + insulin (Type: EXPERIMENTAL): Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
- Insulin scheme alone (Type: ACTIVE_COMPARATOR): Patients assigned to this group will receive only a basal-bolus insulin scheme

Based on this trial design, predict the completion outcome and termination type (if applicable).